Overall clinical experience with aztreonam in the treatment of obstetric-gynecologic infections.
Gynecologic infections (primarily endometritis and pelvic inflammatory disease) in 73 women were evaluated for clinical and microbiologic response to treatment with aztreonam plus clindamycin or a control regimen. The dosage of aztreonam used most frequently was 1 g three times daily. For 72 of the 73 women, a microbiologic cure and a satisfactory clinical response were achieved. Twenty-three of the 73 patients were treated with aztreonam in an open study; all experienced a microbiologic cure and a favorable clinical response. Fifty of the 73 patients treated with aztreonam plus clindamycin were entered into a comparative study that included 38 patients who received gentamicin (3-5 mg/kg per day) plus clindamycin (600 mg three times a day). In 49 (98%) of the aztreonam-treated patients and in 36 (95%) of the gentamicin-treated patients, the causative organism was eradicated, and in 98% and 89% of the patients, respectively, a favorable clinical response was achieved.
D000293:Adolescent; D000328:Adult; D001398:Aztreonam / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002981:Clindamycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005839:Gentamicins / Q000627:therapeutic use; D006088:Gram-Negative Aerobic Bacteria; D006801:Humans; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy
D005839:Gentamicins; D002981:Clindamycin; D001398:Aztreonam